HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 1 matching record:

Displaying record number 62227

HXB2 Location  Rev(52-60)   Rev Epitope Map
View variants at this location
Epitope IHSISERIL   Epitope Alignment
Variants
IrSISERIL   observed variant
IHaISERIL   observed variant
IHSISERIi   observed variant
InSISERIL   observed variant
lHSISERIL   observed variant
IHSlSERIL   observed variant
vHSISERIL   observed variant
Epitope Name Rev-IL9
Species (MHC/HLA human(B*15:10)

Variant Details

Showing all: 7 variant(s).


Variant ID.  4277
Epitope Seq.  IHSISERIL
Variant Seq.  IrSISERIL
Mutations H/R
Epitope Location H2R
HXB2 Location H53R
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note IrSISERIL (H53R) was observed in B*15+ (which is a restricting HLA for IL9) subject 517-C at 0.2 years. However, it does not appear to have been transmitted from the B*15- mother, 517-C. This variant was always observed as a covariant with S54A. It was sometimes also observed alongside L60I.


Variant ID.  4278
Epitope Seq.  IHSISERIL
Variant Seq.  IHaISERIL
Mutations S/A
Epitope Location S3A
HXB2 Location S54A
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note IHaISERIL (S54A) was observed in B*15+ (which is a restricting HLA for IL9) subject 517-C at 0.2 years. However, it does not appear to have been transmitted from the B*15- mother, 517-C. This variant was always observed as a covariant with H53R. It was sometimes also observed alongside L60I.


Variant ID.  4279
Epitope Seq.  IHSISERIL
Variant Seq.  IHSISERIi
Mutations L/I
Epitope Location L9I
HXB2 Location L60I
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note IHSISERIi (L60I) was observed in B*15+ (which is a restricting HLA for IL9) subject 517-C at 0.2 years. However, it does not appear to have been transmitted from the B*15- mother, 517-C. This variant was always observed as a covariant with both H53R and S54A.


Variant ID.  4280
Epitope Seq.  IHSISERIL
Variant Seq.  InSISERIL
Mutations H/N
Epitope Location H2N
HXB2 Location H53N
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note InSISERIL (H53N) was observed to arise in B*15+ (which is a restricting HLA for IL9) subject 517-C between 0.2 and 2.5 years. This variant was sometimes observed as a covariant with I52L, I52V, or I55L.


Variant ID.  4281
Epitope Seq.  IHSISERIL
Variant Seq.  lHSISERIL
Mutations I/L
Epitope Location I1L
HXB2 Location I52L
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note lHSISERIL (I52L) was observed to arise in B*15+ (which is a restricting HLA for IL9) subject 517-C between 0.2 and 2.5 years. It was always observed as a covariant with H53N.


Variant ID.  4282
Epitope Seq.  IHSISERIL
Variant Seq.  IHSlSERIL
Mutations I/L
Epitope Location I4L
HXB2 Location I55L
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note IHSlSERIL (I55L) was observed to arise in B*15+ (which is a restricting HLA for IL9) subject 517-C between 2.5 and 5 years. It was always observed as a covariant with H53N.


Variant ID.  4283
Epitope Seq.  IHSISERIL
Variant Seq.  vHSISERIL
Mutations I/V
Epitope Location I1V
HXB2 Location I52V
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note vHSISERIL (I52V) was observed to arise in B*15+ (which is a restricting HLA for IL9) subject 517-C between 2.5 and 5 years. It was always observed as a covariant with H53N.

References

Leitman2017 Ellen M. Leitman, Christina F. Thobakgale, Emily Adland, M. Azim Ansari, Jayna Raghwani, Andrew J. Prendergast, Gareth Tudor-Williams, Photini Kiepiela, Joris Hemelaar, Jacqui Brener, Ming-Han Tsai, Masahiko Mori, Lynn Riddell, Graz Luzzi, Pieter Jooste, Thumbi Ndung'u, Bruce D. Walker, Oliver G. Pybus, Paul Kellam, Vivek Naranbhai, Philippa C. Matthews, Astrid Gall, and Philip J. R. Goulder. Role of HIV-Specific CD8+ T Cells in Pediatric HIV Cure Strategies after Widespread Early Viral Escape. J. Exp. Med., 214(11):3239-3261, 6 Nov 2017. PubMed ID: 28983013. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health